Condition: Head and Neck Squamous Cell Carcinoma · Sponsor: Merus B.V.
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
This description comes directly from the study's public registry record.
Head of Clinical Operations · +1 617 401 4499 · USenquiries@merus.nl
Always discuss trial participation with your own doctor first.
| Site 164 | Mobile, Alabama, United States | Recruiting |
| Site 36 | La Jolla, California, United States | Recruiting |
| Site 27 | Los Angeles, California, United States | Recruiting |
| Site 16 | Palo Alto, California, United States | Recruiting |
| Site 19 | Newark, Delaware, United States | Recruiting |
| Site 108 | Washington D.C., District of Columbia, United States | Recruiting |
| Site 14 | Fort Myers, Florida, United States | Recruiting |
| Site 48 | Orlando, Florida, United States | Withdrawn |
| Site 8 | Orlando, Florida, United States | Recruiting |
| Site 21 | St. Petersburg, Florida, United States | Recruiting |
| Site 20 | West Palm Beach, Florida, United States | Recruiting |
| Site 171 | Atlanta, Georgia, United States | Recruiting |
+ 193 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06525220